GlassScriptPhysician profile
Devin J Sloan
NPI 1932319878
$1,955.62
in general payments reported to CMS, 2019-2025
26 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $11.39 · 2021: $122 · 2022: $319 · 2023: $312 · 2024: $433 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,156.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $444.17 | 2022-2024 | Pylarify |
| Boston Scientific Corporation | $295.73 | 2021-2025 | Spaceoar Vue System - 10ml |
| Bayer Healthcare Pharmaceuticals INC. | $171.16 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $142.18 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $132.01 | 2023-2024 | Prolaris |
| Abbvie INC. | $86.52 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $84.28 | 2019-2025 | |
| Siemens Medical Solutions USA, INC. | $64.86 | 2025 | Halcyon |
| Varian Medical Systems, INC. | $64.51 | 2019 | |
| Blue Earth Diagnostics | $61.04 | 2023-2025 | Posluma |
| Dendreon Pharmaceuticals LLC | $54.19 | 2023 | Provenge |
| Janssen Biotech, INC. | $49.34 | 2024 | Erleada |
| Celgene Corporation | $46.97 | 2019 | |
| Teleflex LLC | $45.05 | 2025 | Barrigel |
| Puma Biotechnology, INC. | $35.85 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $23.32 | 2019 | |
| Pfizer INC. | $21.40 | 2022 | |
| Rigel Pharmaceuticals, INC. | $18.33 | 2019 | |
| Incyte Corporation | $18.23 | 2019 | |
| Immunitybio, INC. | $17.86 | 2025 | |
| Verity Pharmaceuticals INC. | $17.48 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $13.58 | 2019 | |
| Lilly USA, LLC | $13.45 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.39 | 2020 | |
| Merck Sharp & Dohme LLC | $11.38 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Sloan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.